Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5W5
UPID:
WIF1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y5W5; Q6UXI1; Q8WVG4
Background:
Wnt inhibitory factor 1 plays a crucial role in cellular processes by binding to WNT proteins, thereby inhibiting their activities. This protein is pivotal in the regulation of mesoderm segmentation, a key event in early embryonic development.
Therapeutic significance:
Understanding the role of Wnt inhibitory factor 1 could open doors to potential therapeutic strategies. Its involvement in the WNT signaling pathway suggests its potential in modulating processes critical for tissue development and regeneration.